Horsies and Bunnies: Comparing Antithymocyte Globulin Drugs in Patients Undergoing Allogeneic Stem-Cell Transplant
Crystal Lu, PharmD, BCOP, Nancy Mikulandric, PharmD, BCOP, Meredith Grycki, PharmD, BCOP, BCPS, Vishnuprabha Vogel, PharmD, BCOP, BCPS, Shatha Farhan, MD, Edward Peres, MD, Nalini Janakiraman, MD, Klodiana Neme, PharmD, BCOP
Sarah E. Wheeler, PharmD, Laurie Matt-Amaral, MD, MPH, Chanda Mullen, PhD, Caroline P. Townley, PharmD, BCOP, Melanie L. Boros, PharmD, BCPS, BCACP
Pharmacist-Run Chemotherapy-Induced Nausea and Vomiting Management Protocol Improves Patient Outcomes and Benefits Physician Workflow
David M. Hughes, PharmD, BCOP;, Renee L. Vose, PharmD, Bhavesh Shah, RPh, BCOP, Radhika Jhaveri, PharmD, BCOP
Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared and detrimental adverse events for patients resulting from chemotherapy that can decrease the patient’s quality of life.
Assessing the Impact of Limited Distribution Drug Networks Based on Time to Accessing Oral Oncolytic Agents at an Integrated Specialty Pharmacy
Houston Wyatt, PharmD, CSP, Megan Peter, PhD, Autumn Zuckerman, PharmD, BCPS, AAHIVP, CSP, Josh DeClercq, MS, Leena Choi, PhD, Samuel Starks, PharmD, Matthew Maulis, PharmD, Madan Jagasia, MBBS, MS
Oral oncolytic therapy is increasingly prescribed for patients with hematologic malignancies, but several barriers prevent or delay medication initiation, including insurance approval, financial assistance, limited distribution drug networks, and off-label use. Many oral therapies require insurance approval before they can be dispensed, and patients frequently need financial assistance for copays once a medication is approved.
Impact of Weight-Based Melphalan Dosing Strategies in Autologous Hematopoietic Stem-Cell Transplant for Multiple Myeloma
Risk Factors for Subtherapeutic Tacrolimus Levels After Conversion from Intravenous to Oral Dosing Posttransplant in Adults
Kelsey Konrardy, PharmD, Kane Hosmer, PharmD, BCOP, Michelle Rockey, PharmD, BCOP, FHOPA, Zahra Mahmoudjafari, PharmD, BCOP, Dennis Grauer, MS, PhD, David W. Henry, MS, BCOP, FASHP, Leyla Shune, MD, Joseph McGuirk, DO
Eris Tollkuci, PharmD, BCOP, Anna Chalmers, MD, Kathryn Schultz, PharmD, BCPS, BCOP, Sanjib Basu, PhD, Summer Dewdney, MD, Lydia Usha, MD
Ovarian cancer has an annual incidence of 11.4 per 100,000 women in the United States, with a 5-year overall survival of 47.6% for all stages.1 In patients with fallopian tube or primary peritoneal ovarian cancer, a platinum-based (ie, carboplatin, cisplatin) regimen is the chemotherapy of choice in the metastatic or the adjuvant setting.2
Extended versus Intermittent Infusions of Piperacillin-Tazobactam in Patients with Febrile Neutropenia
Febrile neutropenia requires quick intervention with antipseudomonal beta-lactam antibiotics, such as piperacillin-tazobactam. Previous studies suggest that extended infusions may improve outcomes. The findings in this study show that use of extended infusions of piperacillin-tazobactam led to similar results as intermittent infusions, including defervescence, duration of antibiotic use, mortality, and antibiotic failure.
Robert Walchack, PharmD, BCOP, Jordan Hill, PharmD, BCOP, Sijin Wen, PhD, Aaron Cumpston, PharmD, BCOP
The sudden price increase of injectible calcitonin in 2015 prompted one institution to implement formulary restriction criteria to ensure optimal and cost-effective usee. The findings of this study show that using specific formulary restrictions and use criteria of calcitonin can appropriately reduce utilization and cost without affecting patient outcomes.
Hypersensitivity Rates in Pediatric Patients Receiving Intravenous or Intramuscular Asparaginase Agents
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.1 Current survival rates for pediatric ALL are approaching 90% in the United States.1,2 This has been accomplished by dose intensification, risk stratification, extended treatment duration, and central nervous system prophylaxis.1,2
Page 1 of 7
Results 1 - 10 of 67
Results 1 - 10 of 67